Monthly Archives: January 2008

TMC125: Tick, Tock, Tick, Tock

If you follow any news from the HIV/AIDS market at all, no doubt you’re like us—waiting on pins and needles to hear if FDA will approve Tibotec‘s non-nucleoside reverse transcriptase inhibitor, TMC125. The drug was accepted for priority review by FDA, with a PDUFA date of today. I got tired of checking the company’s Web […]
Posted in Regulatory | Leave a comment

It's Not Just Vytorin. Now Statins are Under Fire

The follow-up to this week’s Vytorin flap has taken an ominous twist. And I’m not just thinking of threatened investigations and lawsuits. A handful of relatively prestigious publications have moved past criticizing Vytorin, Merck, and Schering-Plough and have begun to ask uncomfortable questions about statins in general and the whole idea of lowering cholesterol. In […]
Posted in R&D | 4 Comments

EU Antitrust Officials Raid Pharma Companies

European news sources are reporting that European Union officials conducted surprise dawn raids Wednesday at the offices of a number of pharmaceutical companies, including Pfizer, GlaxoSmithKline, Sanofi-Aventis, AstraZeneca, Merck Sharp & Dohme, Johnson & Johnson’s Belgian unit, Wyeth, and Novartis’ Sandoz division. What’s the beef? Reports say the EU is looking for evidence of patent […]
Posted in Legal, Regulatory | 1 Comment

Pharm Exec News ·Â January 17, 2008

Here are this week’s top news stories, as reported on More Prescriptions Through Learning: The Doctor’s Choice New report finds that neither sales reps nor patient requests are the deciding factor when it comes to physician prescribing habits, information is—the more the better. Click to read>>> (2)008: Licensed to Sell Sales representatives will now […]
Posted in Marketing | Leave a comment

Pharma Buzz Noticeably Absent at JPMorgan's 2008 Healthare Conference

We didn’t get to travel to this year’s JPMorgan Healthcare Conference, but Pharm Exec contributor Audrey S. Erbes (founder of Erbes & Associates) did. Here are her impressions: There was a lack of usual excitement among drug companies but no sense of distress. Although this year’s event broke attendance records with more than 7,700 participants […]
Posted in Deals, Meetings | Leave a comment
  • Categories

  • Meta